Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PBLSthis companyParabilis Medicines, Inc.	$29.55	-0.22×	-2.45×	0×	-0.5×	-183.2%	0.0%	0.0%	0.0%	882.9%	-338.6%	-306.5%	-3.55×	-0.22×	-99.92×	0.52×	0.0%	—	—	2	C+
CBIOCrescent Biopharma, Inc.	$14.11	-0.8×	0.61×	11.39×	0.59×	61.0%	100.0%	-1407.5%	-1419.6%	-75.8%	-74.6%	-117.0%	0.01×	1.41×	-69.85×	6.56×	0.0%	3	11.24	2	C+
CGEMCullinan Therapeutics, Inc.	$11.10	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
CTMXCytomX Therapeutics, Inc.	$2.21	-28.4×	5.93×	7.71×	-36.76×	-283.4%	100.0%	-29.3%	-22.8%	-17.5%	-20.5%	-12.9%	0.04×	0.53×	0×	3.09×	0.0%	1	1.34	2	C
FHTXFoghorn Therapeutics Inc.	$2.08	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
GLUEMonte Rosa Therapeutics, Inc.	$10.64	-26.58×	4.41×	8.31×	-29.87×	222.9%	93.2%	-43.8%	-31.2%	-16.6%	-13.6%	-2.7%	0.17×	2.89×	0×	6.12×	0.0%	2	1.69	2	C+
Peer median	—	-4.58×	1.5×	8.31×	-4.24×	-90.4%	93.2%	-43.8%	-31.2%	-17.5%	-58.7%	-25.3%	0.01×	0.56×	0×	6.12×	0.0%	2	1.69	2	—